For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

FDA and Peptides in 2026: The Regulatory Recap

Research Library › Research Desk

2026 has been an unusually active year for FDA actions on peptides. The agency revised its compounding lists, held an advisory committee vote on seven peptides, sent a draft interim policy to the White House, and issued a wave of warning letters, including several rejecting “research use only” labels. Here is what happened, in order, as of 24 October 2026.

March: GLP-1 marketing and a “research use only” letter

On 3 March the FDA warned 30 telehealth companies over marketing claims for compounded GLP-1 products [8]. On 31 March it sent a warning letter to an online seller. The letter said a “Research Use Only” label did not change the agency’s conclusion that the tirzepatide and retatrutide it sold were unapproved new drugs [5].

April: Category 2 removals and a 503B proposal

On 15–16 April the FDA said it would remove 12 peptides from Category 2, its list of bulk substances that raise significant safety concerns for compounding. They include BPC-157, TB-500, epitalon, injectable GHK-Cu, LL-37, MOTS-c, PEG-MGF, dihexa acetate and Melanotan II. Removal is not an approval and does not by itself allow compounding [1]. On 30 April the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list used by outsourcing facilities. Comments closed on 29 June [4].

July: the advisory committee votes

On 23–24 July the Pharmacy Compounding Advisory Committee (PCAC) voted on seven peptides for the 503A bulks list. It recommended six: BPC-157, TB-500, KPV, Semax, MOTS-c and epitalon. It voted against DSIP [2]. The votes are advisory. FDA decides, and any change to the list requires notice-and-comment rulemaking. The full vote counts are on the regulatory tracker.

August–September: warning letters to RUO sellers

In August the FDA issued warning letters to several online sellers of peptides labeled “research use only.” Products named included survodutide, mazdutide and PT-141 [6]. Law-firm commentary in September read the letters as confirming that the FDA looks at the whole context of a sale, not just the label [6].

October: an interim policy at the White House

On 14 October the FDA sent an interim access policy on compounding certain peptides to the White House Office of Information and Regulatory Affairs for review. Its text and peptide list were not public as of this writing [3]. On 1 October the FDA also updated its consumer page on unapproved GLP-1 drugs, including its warnings about products sold “for research purposes” [7].

What to watch next

  • Publication of the interim peptide access policy [3]
  • A second PCAC meeting before the end of February 2027 on LL-37, injectable GHK-Cu, PEG-MGF, dihexa acetate and Melanotan II [1, 3]
  • A final decision on the 503B GLP-1 proposal [4]
  • Any FDA action on the July PCAC recommendations

We update the FDA Peptide Regulatory Tracker whenever the agency publishes a change.

Sources

  1. Frier Levitt. FDA to remove 12 popular peptides from the Category 2 “do not compound” list. 16 Apr 2026. Link
  2. DLA Piper. FDA AdComm recommends adding six peptides to bulk list. 31 Jul 2026. Link
  3. Holland & Knight. Peptides at a crossroads: what wellness providers need to know about HHS and FDA actions. 16 Oct 2026. Link
  4. U.S. FDA. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list. 30 Apr 2026. Link
  5. U.S. FDA. Warning letter to Gram Peptides, MARCS-CMS 721806. 31 Mar 2026. Link
  6. ArentFox Schiff. RUO-ined: Five peptide vendors learn that “research use only” is not a legal strategy. 18 Sep 2026. Link
  7. U.S. FDA. FDA’s concerns with unapproved GLP-1 drugs used for weight loss (updated 1 Oct 2026). Link
  8. U.S. FDA. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s. 3 Mar 2026. Link

The Kalibra Research Desk reports on published research and regulatory actions. It does not give medical, dosing or usage advice, and nothing here describes use in people or animals. Kalibra Labs products are for laboratory research use only.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top